I'm talking about Viking Therapeutics (NASDAQ: VKTX). Should you forget Eli Lilly and buy this magnificent biotech instead?

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Viking Therapeutics(NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of ...

SAN DIEGO—Matthew Singleton, a director at Viking Therapeutics, Inc. (NASDAQ:VKTX), recently executed a significant stock sale, according to a filing with the Securities and... ByInvesting.com ...

Gainers: EKSO +22%. NDRM +13%. AEMD +9%. ALXN +8%. CRVS +7%.Losers: ATNM -17%. VKTX -11%. APTO -10%. ALDX -10%. RGLS -9%.Now read: Alexion: Suspicions Of Improper ...

Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ULTY offers a 101% distribution yield but has only delivered 2.4% total performance since inception. Read why ULTY ETF's ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...